The Quantellect read.As of Nov 19, 2026, 24 active firms cover Kymera Therapeutics Inc: 22 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $100.00 to $170.00, a moderate spread. The average target of $133.78 sits 10% above the current $121.19. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 19 to 22 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.35 next quarter toward $-5.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS24 active firms
Buy
Strong Buy00%
Buy2292%
Neutral28%
Sell00%
Strong Sell00%
Based on 24 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$133.78
+10.4% upside
Average target across 23 active firms as of Nov 19, 2026 vs $121.19 current
Highest Target$170.00
Average Target$133.78
Lowest Target$100.00
Detailed analyst forecasts for KYMR
Showing 1–25 of 26 named analysts shown · 24 active firms in the rating projection
As of Nov 19, 2026, 22 of 24 active firms rate KYMR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KYMR EPS & revenue forecast
EPS · NEXT QUARTER
$-1.35
Range $-1.52 – $-1.08 · 7 analysts · +90% YoY
Next period, 7 analysts expect Kymera Therapeutics Inc to earn $-1.35 a share (range $-1.52 – $-1.08), versus $-0.71 a year earlier. Full-year consensus is $-3.93, growing to $-5.12 the year after.
REVENUE · NEXT QUARTER
$7.0M
Range $0 – $20.0M · 7 analysts · -80% YoY
Revenue is expected to reach $7.0M (range $0 – $20.0M), -79.6% year-over-year. Full-year consensus is $99.4M, rising to $42.0M next year.
Top analysts covering Kymera Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KYMR.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$155.00+27.9% to target
Overall win rate
49%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$134.00+10.6% to target
Overall win rate
45%
+ Follow
#3
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$100.00-17.5% to target
Overall win rate
47%
+ Follow
#4
Brian Cheng
JP Morgan · Rank #87
Buy
$140.00+15.5% to target
Overall win rate
51%
+ Follow
#5
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$129.00+6.4% to target
Overall win rate
44%
+ Follow
KYMR stock forecast FAQ
What is KYMR's average 12-month price target?+
The 23 active firms with a live target average $133.78 for Kymera Therapeutics Inc over the next 12 months, ranging from a $170.00 high to a $100.00 low, as of Nov 19, 2026.
Is KYMR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 24 active firms as of Nov 19, 2026, 22 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KYMR?+
The Street-high target is $170.00 (Guggenheim), and the Street-low is $100.00 (Stephens & Co.). The average of all 23 active-firm targets is $133.78.
How many active Wall Street firms cover KYMR?+
24 active firms have a recognized rating on Kymera Therapeutics Inc as of Nov 19, 2026, and 23 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KYMR?+
Among analysts who currently cover KYMR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $155.00 target.
What is Kymera Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.35 per share (range $-1.52 – $-1.08) across 7 analysts. Full-year EPS is projected at $-3.93, rising to $-5.12 the following year.
How much revenue is Kymera Therapeutics Inc expected to report next quarter?+
Consensus revenue is $7.0M (range $0 – $20.0M). Full-year revenue is projected at $99.4M, growing to $42.0M next year.
Have analysts been upgrading or downgrading KYMR lately?+
As of Nov 19, 2026, 22 of 24 active firms rate KYMR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KYMR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.